Latest Articles

Publication Date
Immunotherapy for High-Grade Endometrial Stromal Sarcoma: A Narrative Review Bridging Molecular Insights to Clinical Translation - Frontiers

Immunotherapy for High-Grade Endometrial Stromal Sarcoma: A Narrative Review Bridging Molecular Insights to Clinical Translation Frontiers

Published: Aug. 25, 2025, 10:47 a.m.
TET3 is a common epigenetic immunomodulator of pathogenic macrophages.

Through a combination of single-cell/single-nucleus RNA-sequencing (sc/snRNA-seq) data analysis, immunohistochemistry, and primary macrophage studies, we have identified pathogenic macrophages characterized by TET3 overexpression (Toe-Macs) in three major human diseases associated …

Published: Aug. 12, 2025, midnight
Immunotherapy plus chemotherapy approved for endometrial cancer - The Pharmaceutical Journal

Immunotherapy plus chemotherapy approved for endometrial cancer The Pharmaceutical Journal

Published: Aug. 7, 2025, 2:48 p.m.
Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive

Breakthrough treatment combines immunotherapy and chemotherapy National Health Executive

Published: Aug. 7, 2025, 8:48 a.m.
NICE approves first immunotherapy combination for endometrial cancer - Wired Gov

NICE approves first immunotherapy combination for endometrial cancer Wired Gov

Published: Aug. 6, 2025, 1:13 p.m.
First immunotherapy combination for endometrial cancer approved by NICE - Oncology Central

First immunotherapy combination for endometrial cancer approved by NICE Oncology Central

Published: Aug. 6, 2025, 11:18 a.m.
First immunotherapy for advanced endometrial cancer approved in the UK - Open Access Government

First immunotherapy for advanced endometrial cancer approved in the UK Open Access Government

Published: Aug. 6, 2025, 8:50 a.m.
NICE approves first immunotherapy combination for endometrial cancer - NICE website

NICE approves first immunotherapy combination for endometrial cancer NICE website

Published: Aug. 5, 2025, 11 p.m.
B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight - The Malaysian Reserve

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight The Malaysian Reserve

Published: July 24, 2025, 10:55 p.m.
Gastric ectopic pancreatic ductal adenocarcinoma coexisted with endometriosis mimick advanced disease: a case report and literature review.

Ectopic pancreas (EP) is most commonly located in the upper gastrointestinal tract, particularly in the stomach. Malignant transformation of EP is exceptionally rare, and due to its very low incidence, …

Published: July 24, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!